Open AccessEffect of genetic variation in Notch regulator DTX1 on SCLC prognosis compared with the effect on NSCLC prongosis
Author(s) -
Yoo Seung Soo,
Lee Jang Hyuck,
Hong Mi Jeong,
Choi Jin Eun,
Kang HyoGyoung,
Do Sook Kyung,
Kim Ji Hyun,
Baek Sun Ah,
Choi Sun Ha,
Lee Won Kee,
Lee Yong Hoon,
Seo Hyewon,
Lee Jaehee,
Lee Shin Yup,
Cha Seung Ick,
Kim Chang Ho,
Park Jae Yong
Publication year - 2020
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13566
Subject(s) - medicine , hazard ratio , oncology , odds ratio , confidence interval , lung cancer , chemotherapy , allele , regulator , biology , genetics , gene
Deltex‐1 (DTX1) is a negative regulator of the Notch signaling pathway. Here, we investigated the clinical effect of DTX1 rs1732786A > G, which is associated with better prognosis in patients with early‐stage non‐small cell lung cancer (NSCLC), in 261 patients with small cell lung cancer (SCLC). DTX1 rs1732786A > G was associated with a significantly worse chemotherapy response and lower overall survival in the codominant model (odds ratio = 0.42, 95% confidence interval [CI]: 0.26–0.66, P = 2 × 10 −4 ; hazard ratio = 1.47, 95% CI: 1.17–1.84, P = 0.001, respectively). An in vitro luciferase assay was performed, and the 1732786G allele demonstrated significantly higher promoter activity than the 1732786A allele ( P = 2 × 10 −7 ). In summary, DTX1 rs1732786A > G was associated with poor prognosis in patients with SCLC as opposed to patients with NSCLC. Key points Significant findings of the study DTX1 rs1732786A > G was associated with better prognosis in patients with early‐stage non‐small cell lung cancer (NSCLC) in our previous study. What this study adds DTX1 rs1732786A > G was associated with a significantly worse chemotherapy response and lower overall survival in small cell lung cancer (SCLC).